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Objective: This study aimed to determine the effects of subthalamic
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Methods: The clinical data of 57 patients with PD who underwent bilateral
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analyzed. Patient scores on the Unified Parkinson’s Disease Rating

distributed under the terms of Creative
Commons Attribution 4.0 International
License (CC BY).

nucleus deep brain stimulation (STN-DBS) on anxiety and depression in
Parkinson’s disease (PD) patients.
STN-DBS between March and December 2018, were retrospectively
Scale-Part III (UPDRS-Ⅲ), the Hamilton Anxiety Rating Scale (HAM-A),
the Hamilton Depression Rating Scale (HAM-D), and the Parkinson’s
Disease Questionnaire (PDQ-39) were evaluated.
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6-month follow-ups. The average patient improvement rates for HAM-A
and HAM-D scores at the 6-month follow-up were 41.7% [interquartile
range (IQR) 34.9%] and 37.5% (IQR 33.4%), respectively (both p < 0.001).
There were positive correlations between both the rate of improvement
in HAM-A scores and the rate of improvement in PDQ-39 scores (r =
0.538, p < 0.001), and between the rate of improvement in HAM-D scores
and the rate of improvement in PDQ-39 scores (r = 0.404, p = 0.002) at the
6-month follow-up. HAM-A and HAM-D scores were positively
correlated with the Parkinson’s Hoehn-Yahr disease stage (r = 0.296, p =
0.025; and r = 0.380, p = 0.004, respectively).
Conclusion: Bilateral STN-DBS can improve symptoms of anxiety and
depression in PD patients.
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1

Introduction

Parkinson’s disease (PD) is a common degenerative
movement disorder of the extrapyramidal system.
Deep brain stimulation (DBS) is an effective
treatment for the motor symptoms of advanced
PD [1]. Anxiety and depression are common
non-motor symptoms in PD patients and can
seriously affect the patient’s quality of life but
the effect of DBS on symptoms of anxiety and
depression in Parkinson’s disease is unclear.
Some studies have shown that DBS can improve
symptoms of anxiety and depression in patients
with PD [2], while others have found the opposite
[3]. We explored the effect of subthalamic nucleus
DBS (STN-DBS) on anxiety and depression in
PD patients.

2 Materials and methods
We conducted a retrospective evaluation of 57
patients with advanced PD who underwent
bilateral STN-DBS between March 2018 and
December 2018 at the Beijing Tiantan Hospital
Affiliated with Capital Medical University, the
First Hospital of Hebei Medical University,
and the General Hospital of Ningxia Medical
University.
The study was approved by the Medical Ethics
Committee of the First Hospital of Hebei Medical
University (No. 20210366). We adhered to
the tenets of the 1964 Declaration of Helsinki
throughout this research. All patients provided
written informed consent to participation and
publication.
2.1

Patient selection

Patients diagnosed with advanced idiopathic PD
based on the UK Parkinson’s Disease Society Brain
Bank diagnostic criteria [4] who underwent
bilateral STN-DBS at the Beijing Tiantan Hospital
between March 2018 and December 2018, based

on PD surgical treatment evaluation criteria [5]
were selected for inclusion in this study. Exclusion
criteria were serious cognitive impairment,
dementia, or mental illness, and those with severe
depression [the Hamilton Depression Rating
Scale (HAM-D) scores > 29] and severe anxiety
[the Hamilton Anxiety Rating Scale (HAM-A)
scores ≥ 29). We also excluded those receiving
pharmaceutical treatment for their depression
or anxiety, such as selective serotonin reuptake
inhibitors (SSRIs). We used an acute levodopa
challenge test to assess dopaminergic responsiveness and predict the postoperative efficacy
of STN-DBS. A predicted improvement rate of
> 30% was considered an indication for surgery.
2.2

Clinical evaluation

Around PD patients were assessed using an air
ramble specifies the demographic characteristics.
Disease severity was assessed with the Unified
Parkinson’s Disease Rating Scale-Ⅲ (UPDRS-III)
[6]. The Hoehn-Yahr scale [7] was used for disease
staging. The therapeutic medical regimen was
recorded, and we calculated the levodopa
equivalent dose (LEDD) using the method of
Tomlinson et al. [8]. Anxiety outcomes were
assessed using the HAM-A (14 parts). HAM-A
scores range from 0 (no anxiety) to 56 (maximum
anxiety). Depression outcomes were assessed
using HAM-D (24 parts). HAM-D scores range
from 0 (no depression) to 68 (maximum depression). Quality of life was assessed using
the 39-item Parkinson’s Disease Questionnaire
(PDQ-39), with total possible scores ranging from 0
(no impairment) to 124 (maximum impairment).
Postoperative improvement rate was calculated as
preoperative score  postoperative score
 100%.
preoperative score

Symptoms of anxiety and depression were
evaluated both pre- and postoperatively. Clinical
Journal of Neurorestoratology
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assessments were performed at a preoperative
baseline (without dopaminergic treatment,
indicated as Med-OFF), and 1, 3, 6 months after
surgery.
2.3

Surgical procedures

Surgical implantation of the STN-DBS was
performed on all patients in this study. We have
described the surgical procedure in a previous
study [9].
2.4

Stimulation programming

One month after surgery, we turned on the
stimulator and programmed the implantable pulse
generator (IPG) [10]. We tested the contacts on
each electrode, and selected the best stimulation
target, i.e., that with which the patient obtains
satisfactory improvement with minimal side
effects. If necessary, the parameters can be
adjusted remotely at a later date. The DBS
system provides video communication, remote
programming, and postoperative follow-up
functions, enabling doctors to adjust stimulation
parameters for patients with network connections
[11]. We begin each patient with the unipolar
stimulation mode, for which the stimulation
parameters are: voltage, 1.5–2.0 V; frequency,
130 Hz; pulse width, 60 ms. Then, we gradually
adjust the stimulation parameters until the best
therapeutic effect is achieved.
2.5

Statistical analyses

All statistical analyses were performed using IBM

SPSS Statistics for Windows (v. 25, IBM Corp.,
Armonk, N.Y., USA). Continuous variables
that did not have a normal distribution were
presented as the median and interquartile range
(IQR). The Friedman test was used for continuous
variables that did not have a normal distribution
and the Kruskal–Wallis rank-sum test was used
for comparisons between multiple groups. Pearson
correlation analysis was used to determine which
factors were associated with improvements in
anxiety and depression after DBS. The statistical
significance level was set at p < 0.05.

3 Results
3.1

Patient population

The study group comprised 34 males and 23
females. The preoperative LEDD of the 57 patients
ranged 125–1625 mg/d, the average was 866.3 ±
357.0 mg/d.
3.2

Clinical outcomes

Our comparisons between preoperative and
postoperative evaluations are summarized in
Table 1 and Fig. 1. The improvement rates of
HAM-A scores at 1, 3, and 6 months were 23.5%
(IQR 34.9%), 33.3% (IQR 30.9%), and 41.7% (IQR
34.9%), respectively (all p < 0.001). The improvement rates of HAM-D scores at 1, 3, and 6
months were 20.0% (IQR 33.3%), 31.0% (IQR
32.7%), and 37.5% (IQR 33.4%), respectively (all
p < 0.001). The improvement in the UPDRS-III

Table 1 Comparison of preoperative and postoperative HAM-A and HAM-D scores.
Time

Preoperative*

HAM-A (0–56)
HAM-D (0–68)

Postoperative*

Total p

χ2

p1

p2

p3

11 (11)

< 0.001

60.464

< 0.001

< 0.001

< 0.001

9 (9)

< 0.001

45.592

< 0.001

< 0.001

< 0.001

1 month

3 months

6 months

16 (14)

11 (11)

9 (10)

14 (13)

9 (9)

9 (8)

HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale.
The p1, p2, and p3 values are for comparisons between the preoperative results and the results 1, 3, and 6 months after surgery,
respectively.
*Data is shown as median (IQR).
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Fig. 1 Comparison of preoperative and postoperative HAM-A and HAM-D scores. (A) HAM-A scores were improved
by 41.7% (IQR 34.9%) at the 6-month follow-up. (B) HAM-D scores were improved by 37.5% (IQR 33.4%) at the 6-month
follow-up. ** p < 0.001; Baseline = preoperative; FU1 = follow-up 1 month after surgery; FU2 = follow-up 3 months after
surgery; FU3 = follow-up 6 months after surgery.

scores (Med-OFF) was 55.42% and in the PDQ-39
scores was 47.39%, but the LEDDs decreased by
an average of 40.10% 6 months after surgery.
3.3

Correlation analyses

The results of the correlational analysis of the
improvement rate of UPDRS-III scores (MedOFF) and the improvement rates of HAM-A and
HAM-D scores are shown in Table 2. There was no
significant correlation between the improvement
rates of either HAM-A or HAM-D scores and the
improvement rate of UPDRS-III scores (MedOFF) 6 months after surgery (p > 0.05).
The results of the correlational analysis of the
improvement rates in HAM-A and HAM-D scores
and the improvement rate in PDQ-39 scores are
shown in Table 3. The improvement rates in both
HAM-A and HAM-D scores were positively
correlated with the improvement rate in PDQ-39
scores 6 months after surgery (r = 0.538, p < 0.001
and r = 0.404, p = 0.002, respectively).
The results of the correlational analysis of the
improvement rates in HAM-A and HAM-D
scores and the LEDD reduction rate 6 months
after surgery are shown in Table 4. There was no
significant correlation between the improvement
rates in HAM-A or HAM-D scores and the LEDD

reduction rate six months after surgery (p > 0.05).
The results of our correlational analysis of
HAM-A, HAM-D, PDQ-39, and UPDRS-III scores,
and clinical variables are shown in Table 5. There
were no correlations between HAM-A or HAM-D
scores and age or disease duration (p > 0.05).
Table 2 Analysis for correlations between the improvement
rate of HAM-A, HAM-D, and PDQ-39 scores and the
improvement rate in UPDRS-III scores (Med-OFF) 6 months
after surgery.
Improvement
rate (%)

DBS motor symptoms
improvement rate
(Med-OFF) (%)

HAM-A

34.27

55.42

0.071 0.600

HAM-D

26.95

55.42

−0.033 0.810

r

p

HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton
Depression Rating Scale; DBS, deep brain stimulation; PDQ-39,
the Parkinson’s Disease Quesionnaire; UPDRS-III, the Unified
Parkinson’s Disease Rating Scale-Part III.
Table 3 Analysis for correlations between the improvement
rate in HAM-A and HAM-D scores and the improvement rate
in PDQ-39 scores 6 months after surgery.
Improvement
rate (%)

PDQ-39 scores
improvement
rate (%)

r

p

HAM-A

34.27

47.39

0.538

< 0.001

HAM-D

26.95

47.39

0.404

0.002

HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton
Depression Rating Scale; PDQ-39, the Parkinson’s Disease
Quesionnaire.
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Table 4 Analysis for correlations between the improvement
rate in HAM-A and HAM-D scores and the LEDD reduction
rate 6 months after surgery.
Improvement LEDD reduction
rate (%)
rate (%)

r

p

HAM-A

34.27

40.10

0.035

0.798

HAM-D

26.95

40.10

−0.037

0.786

HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton
Depression Rating Scale; LEDD, the levodopa equivalent dose.
Table 5 Analysis for correlations between HAM-A and
HAM-D scores and clinical variables 6 months after surgery.
Age

Disease duration

Hoehn-Yahr
scale

r

p

r

p

r

p

HAM-A

−0.062

0.655

0.091

0.511

0.296

0.025

HAM-D

−0.096

0.485

0.074

0.586

0.380

0.004

HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton
Depression Rating Scale.

There was a positive correlation between both
HAM-A and HAM-D scores and Hoehn-Yahr
scale (r = 0.296, p = 0.025 and r = 0.380, p = 0.004,
respectively).

4 Discussion
PD is a common neurodegenerative disease
affecting motor function. The symptoms result
from the degeneration and loss of dopaminergic
neurons in the substantia nigra and the formation
of -synuclein-positive Lewy bodies [12], a
pathological marker of PD. The presence of
Lewy bodies in areas other than the midbrain
dopaminergic neurons is considered the pathological basis of most non-motor symptoms of PD
[13]. DBS is widely used in the clinical treatment
of PD because it is minimally invasive, adjustable,
reversible, and efficacious. Although most PD
patients experience non-motor symptoms such
as anxiety and depression at some stage of
the disease [14], the relationship between the
disease and these mental health issues is unclear
[15]. The cortico-basal ganglia-thalamocortical
(CBGTC) circuit in the brain [16], incorporates

several smaller neural networks. These are a
motor, an oculomotor, a dorsolateral prefrontal,
a lateral orbitofrontal, and an anterior cingulate
circuit. The frontal loops, also known as coordination loops, include the dorsolateral prefrontal
circuit, and the lateral orbitofrontal circuit. The
frontal circuit is involved in cognition, emotion,
and behavior [16]. The CBGTC receives input
from the striatum and the subthalamic nucleus
(STN). The STN is the stimulation area of the DBS
devices used to treat PD. It can be anatomically
divided into three functional subregions [16]:
a dorsolateral motor region, an intra-ventral
coordination region, and a medial limbic region.
These are associated with movement, coordination,
and emotion, respectively.
Depression is one of the most common nonmotor symptoms in PD patients. Around 40%–
50% of PD patients suffer from depression, with
5%–10% developing severe depression [17]. The
reported effects of DBS on depression vary widely.
Some studies suggest that DBS can aggravate
depressive symptoms [18], arguing that stimulation
of brain regions involved in behavior can induce
a range of disorders, of which depression and
anxiety are symptoms [19]. Others have reported
significant improvements in depressive symptoms
resulting from DBS [20]. Another study found
that DBS can improve non-motor symptoms,
including depression, in the short term, but
symptoms eventually return to preoperative levels
[21]. Further conflicting findings found neither
improvement nor worsening of depressive
symptoms in PD patients after DBS [22]. In our
study, the improvement rate in HAM-D scores
was 37.5% (IQR 33.4%, p < 0.001) 6 months after
the operation. Although we excluded patients
with severe depression, our patients with mild
and moderate depression showed significant
symptomatic improvements after undergoing
STN-DBS. None of the patients in our cohort were
receiving pharmacological treatment for anxiety

36

or depression. The improvement in depression
following bilateral STN-DBS surgery may be
attributed to various factors. Firstly, the nerve
stimulation of DBS increases dopamine levels in
the brain [23]. Dopamine is strongly associated
with happiness and well-being so its increased
expression may have sufficient positive effects
on mood to counter depression. Secondly, the
improvement to motor function resulting from
the DBS will improve quality of life, which in
turn may reduce depression. Thirdly, bilateral
STN-DBS stimulation can directly inhibit the
marginal subregion of the STN and indirectly
affect the CBGTC loop. This, in turn, may affect
mood and control depressive symptoms [24].
STN-DBS may also regulate mood in PD patients
through its effect on other monoaminergic neurons,
such as the serotonergic neurons of the median
raphe nucleus and the noradrenergic neurons
of the locus coeruleus [25]. Since the conflicting
findings of previous studies suggest a possible
risk that STN-DBS may promote or exacerbate
depression in PD patients, it is extremely important
to evaluate depressive symptoms several times
during the perioperative period. Previous research
found no significant correlation between the
incidence of depression in PD and PD severity [26].
It has been posited that depressive symptoms may
have multiple causes, including the degeneration of the substantia nigra striatum, as well as
psychological and environmental factors. The
relationship between implantation of the STNDBS and reduction in levodopa treatment may
have some causative influence on the increase
in depressive symptoms [27, 28]. However, we
did not observe any exacerbation of depression
following STN-DBS in our study.
At the 6-month follow-ups, the patients’
LEDD had decreased by an average of 40.10%, a
significant reduction in drug dosage. Despite the
reduction or cessation of monoamine oxidase

Journal of Neurorestoratology

B inhibitors, dopamine agonists, and catecholO-methyl transferase inhibitors, depressive
symptoms still improved significantly. We might
infer that STN-DBS improves the symptoms of
PD depression but it is also possible that the
reduction in levodopa was responsible for
these improvements. It may also have been a
combination of the two. This question requires
further study.
Anxiety is also a frequent secondary symptom
of PD, affecting about 40% of PD patients [17].
Previous studies have reported significant improvements in anxiety after STN-DBS [29] and
this was supported by our study. We saw an
improvement rate in HAM-A scores of 41.7%
(IQR 34.9%, p < 0.001) at 6-month follow-ups.
Fluctuations in anxiety and depression are
correlated with changes to quality of life. Previous
studies have demonstrated a significant correlation
between improvements in depression and anxiety
and improvements in quality of life after STN-DBS
[16, 30, 31]. Similar relationship was also showed
in this study. In our study, the improvement
rates in both HAM-D and HAM-A scores were
positively correlated with the improvement
rate in PDQ-39 scores (r = 0.404, p = 0.002 and
r = 0.538, p < 0.001, respectively). Thus, improved
quality of life after STN-DBS is closely associated
with reductions in depression and anxiety in PD
patients.
Although some warn against reducing
dopaminergic therapy too soon after STN-DBS,
it seems that the STN-DBS can compensate for
LEDD reduction without risking psychiatric
consequences [32]. The reduction of LEDD in the
patients in our study was implemented over the
first month after surgery with no disturbances to
patients’ mental health observed.
Both HAM-A scores (r = 0.296, p = 0.025) and
HAM-D scores (r = 0.380, p = 0.004) were positively
correlated with the Hoehn-Yahr grades of the
Journal of Neurorestoratology
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patients, indicating that, as the severity of PD
increases, there was a corresponding increase in
anxiety and/ or depression. To obtain the best
outcomes, DBS surgery should therefore be considered suitable for PD patients at Hoehn-Yahr
stages 2.5–4.0.

written informed consent.

Limitations

Funding

This study had three main limitations. Firstly,
the evaluation tools used (the HAM-A and
HAM-D questionnaires) allow a certain degree
of subjectivity both in the evaluation of patient
anxiety and depression and in the interpretation
of the associated scales. This may cause different
assessors to obtain different results. Secondly, the
final postoperative follow-up was at 6 months,
so we were unable to evaluate the long-term
effects of DBS on anxiety and depression. Thirdly,
patients with severe depression before surgery
were not included in the study, so we do not
know the effects of DBS on severe depression.

5 Conclusion
Bilateral STN-DBS can improve symptoms of
anxiety and depression in PD patients. Future
studies should pay more attention to the evaluation
of non-motor symptoms of Parkinson’s disease,
especially anxiety and depression symptoms.
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